natgillin/translations-raw huggingface dataset:
Parkinsonism (including Parkinson’s disease) and dementia with Lewy bodies.
parkinsonizmu (vključno s Parkisonovo boleznijo) in demenci, povezani z Lewyjevimi telesci
Parkinsonism 6
akatizija6 parkinsonizem
Parkinsonism 6
parkinsonizem
Parkinsonism events followed in frequency of 6.9 % for Abilify Maintena, 4.15 % for oral aripiprazole 10-30 mg tablets and 3.0 % for placebo, respectively.
Sledili so dogodki parkinsonizma, in sicer z naslednjo pogostnostjo: 6,9 % pri zdravilu Abilify Maintena, 4,15 % pri aripiprazolu v 10–30 mg peroralnih tabletah in 3,0 % pri placebu.
Parkinsonism** Dizziness Dystonia*** Dyskinesia
parkinsonizem** omotica distonija*** diskinezija
Parkinsonism6
Diskinezije6
Parkinsonism6
Parkinsonizem6
parkinsonism: slow movements, with tremor, stiffness and a shuffling walk
parkinsonizem: upočasnjeni gibi, tremor, okorelost in drsajoča hoja
parkinsonism; this is a medical term that includes several symptoms such as muscle stiffness, jerks when bending the limbs, slow or impaired body movements, no expression on the face, muscle tightness, shuffling, hurried steps and lack of normal arm movements when walking
parkisonizem; to je medicinski izraz, ki vključuje več simptomov, kot so mišična togost, nehoteni gibi, počasno ali moteno gibanje telesa, brezizraznost obraza, napetost mišic, negotovi, hitri koraki in odsotnost normalnega gibanja rok pri hoji,
parkinsonismb,
parkinsonizemb,
parkinsonismb,
parkinsonizemb, akatizijab,
parkinsonismb, akathisiab,
parkinsonizemb, akatizijab,
parkinsonismc,
parkinsonizemc,
Parkinson’s disease
Parkinsonova bolezen
Parkinson’s disease
Parkinsonova bolezen, najpogostnejši neželeni učinki
Parkinson’s disease
Parkinsonovo bolezen
Parkinson’s disease (worsening)
Parkinsonova bolezen (poslabšanje)
Parkinson’s disease (worsening)
Rigidnost s fenomenom zobatega kolesa
Parkinson’s disease (worsening) Bradykinesia
Parkinsonova bolezen (poslabšanje) bradikinezija
Parkinson’s disease (worsening) Bradykinesia
Parkinsonova bolezen (poslabšanje) bradikinezija diskinezija
Parkinson’s disease (worsening) Salivary hypersecretion Dyskinesia
Parkinsonova bolezen (poslabšanje)
Parkinson’s disease and dementia with Lewy bodies
Parkinsonova bolezen in demenca z Lewyevimi telesci
Parkinson’s disease and dementia with Lewy bodies
Parkinsonova bolezen in demenca z Lewyjevimi telesci
Parkinson’s disease is a progressive brain disorder that causes shaking, slow movement and muscle stiffness.
Parkinsonova bolezen je napredujoča bolezen možganov, ki povzroči tresenje, počasno gibanje in okorelost mišic.
Parkinson’s disease is a progressive brain disorder that causes shaking, slow movement and muscle stiffness.
Parkinsonova bolezen je napredujoča okvara možganov, ki povzroča tresenje, upočasnjeno izvajanje gibov in otrdelost mišic.
Parkinson’s disease is a progressive brain disorder that causes shaking, slow movement and muscle stiffness.
Parkinsonova bolezen je napredujoča okvara možganov, ki povzroča tresenje, upočasnjeno izvajanje gibov in otrplost mišic.
Parkinson’s disease is caused by low levels of a substance called dopamine in the brain.
Parkinsonovo bolezen povzročajo nizke ravni snovi, ki se imenuje dopamin, v možganih.
Parkinson’s disease)
Parkinsonove bolezni)
Parkinson’s disease, a progressive brain disorder that causes shaking, slow movement and muscle stiffness.
Parkinsonove bolezni, napredujoče okvare možganov, ki povzroča tresavico, upočasnjeno izvajanje gibov in otrplost mišic.
Parkinson’s disease, most common adverse effects
Parkinsonova bolezen, najpogostejši neželeni učinki
Parkinson’s disease, most common adverse reactions
Oftalmološki pregledi
Parkinson’s disease, most common adverse reactions
Parkinsonova bolezen, najpogostnejši neželeni učinki
Parkinson’s disease.
Parkinsonove bolezni.
Parodoxical bronchospasm
Paradoksni bronhospazem
Paronychia1
paronihija1
Paronychiag
paronihijag
Parosmia
driska
Paroxetine (CYP2D6 inhibitor and substrate)
Paroksetin (zaviralec in substrat encima CYP2D6)
Paroxetine - The strong CYP2D6 inhibitor paroxetine increased the systemic exposure of lasofoxifene by 35% which is not considered to be clinically meaningful.
Paroksetin – Močni inhibitor CYP2D6 paroksetin je zvečal sistemsko izpostavljenost lasofoksifenu za 35 %, kar ne velja za klinično pomembno.
paroxetine Cmin ↓ 37%
paroxetin AUC ↓ 39% paroxetin Cmin ↓ 37% paroxetin Cmax ↓ 36
Paroxetine exposure (AUC0-24) increased by 1.7 fold and Cmax increased by 1.5 fold.
Izpostavljenost paroksetinu (AUC0–24) se je povečala za 1,7-krat, Cmax. pa za 1,5-krat.
paroxetine without dose
paroksetinom brez
paroxetine, fluoxetine, fluvoxamine, duloxetine, bupropion, moclobemide – antidepressants (used to treat depression)
paroksetin, fluoksetin, fluvoksamin, duloksetin, bupropion, moklobemid – antidepresivi (uporabljajo se za zdravljenje depresije)
Paroxetine/efavirenz (20 mg once daily/600 mg once daily)
(20 mg enkrat na dan/600 mg
Paroxetine/Efavirenz (20 mg q.d./600 mg q.d.)
ertralin/dizoproksiltenofovirijev fumarat paroksetin/efavirenz (20 mg dnevno/600 mg dnevno)
Paroxetine: AUC  55%
primerjava s preteklimi podatki
Paroxetine: AUC: ↔
paroksetin: AUC: ↔
Paroxetine: Cmax  51%
paroksetin: Cmax  51
paroxysmal nocturnal haemoglobinuria (PNH);
paroksizmalno nočno hemoglobinurijo (PNH);
Paroxysmal nocturnal hemoglobinuria
Paroksizmalna nočna hemoglobinurija
Part 1
1. časť
Part I: Preparing and Injecting
del: Priprava in injiciranje
Part II: In the withdrawal period of the pivotal study, the primary endpoint was defined as the proportion of patients with a disease relapse/flare: none (0%) of the patients randomised to Ilaris flared, compared with 81% of the patients randomised to placebo.
2. obdobje: V obdobju opuščanja zdravila te ključne študije je bil primarni cilj opazovanja opredeljen kot delež bolnikov s ponovitvijo/zagonom bolezni: do ponovnega zagona ni prišlo pri nobenem (0 %) od bolnikov, ki so bili randomizirani na uporabo zdravila Ilaris, v primerjavi z 81 % bolnikov, ki so bili randomizirani na uporabo placeba.
Part II: Storage and Maintenance
del: Shranjevanje in vzdrževanje
PART III: BETAFERON MEDICATION RECORD
DEL III: KARTICA O UPORABI ZDRAVILA BETAFERON
Part III: Needles for the NutropinAq Pen
del: Igle za injekcijski peresnik NutropinAq Pen
Part III: Patients treated with placebo in Part II who flared regained and maintained clinical and serological response following entry into the open-label Ilaris extension.
3. obdobje: Pri bolnikih, ki so v 2. obdobju prejemali placebo in pri katerih je prišlo do zagona bolezni, je po vključitvi v podaljšanje z odprtim zdravljenjem z zdravilom Ilaris ponovno prišlo do kliničnega in serološkega odziva, ki se je tudi ohranil.
Part IV: Commonly Asked Questions
del: Pogosto zastavljena vprašanja
Part of a multi-pack of 2 x (5 x 3ml) cartridges.
Del večjega pakiranja 2 x (5 x 3 ml) vložki.
Part of a multi-pack of 2 x (5 x 3ml) pre-filled pens.
Del večjega pakiranja 2 x (5 x 3 ml) napolnjeni injekcijski peresniki.
Part of a multi-pack of 3 x (4 single dose kits).
Veliko pakiranje 3 x (4 enoodmerni seti).
Part of a multi-pack.
Del večdelnega pakiranja.
Part of a multipack containing 168 (4 x 42) ampoules with 1 ml co-packed with Breelib consumables set (containing 1 mouthpiece and 1 medication chamber).
Del škatle večkratnega pakiranja, ki vsebuje 168 (4 x 42) ampul z 1 ml s priloženim setom za uporabo nebulatorja Breelib (1 ustnik in 1 prostor za zdravilo).
Part of a pack containing 14 single packs in a 2-month pack of 2x14 single packs.
Del pakiranja vsebuje 14 posameznih pakiranj v 2-mesečnem pakiranju z 2 x 14 posameznimi pakiranji.
Part of a pack containing 14 single packs in a 3-month pack of 3x14 single packs.
Del pakiranja vsebuje 14 posameznih pakiranj v 3-mesečnem pakiranju s 3 x 14 posameznimi pakiranji.
Part of a pack containing 15 single packs in a 3-month pack of 3x15 single packs.
Del pakiranja vsebuje 15 posameznih pakiranj v 3-mesečnem pakiranju s 3 x 15 posameznimi pakiranji.
Part of the decrease can be attributed to excretion of 64Cu into the bile, urine and faeces.
Delno zmanjšana radioaktivnost se lahko pripiše izločanju bakra (64Cu) v žolč, urin in blato.
part of the hepatitis C
sheme za hepatitis
Part of the Repatha pre- filled pen may be broken even if you cannot see the break.
V takšnem primeru je lahko del napolnjenega injekcijskega peresnika zdravila Repatha počen, čeprav ne vidite razpoke.
part of your stomach has been removed (partial gastrectomy) as the reliability of the test has not been proven in these patients.
če so vam odstranili del želodca (delna gastrektomija), ker pri teh bolnikih zanesljivost testa še ni bila dokazana.
Part the coat until the skin is visible.
Razmaknite dlako do kože.
Part the fur on the cat’s neck at the base of the skull until the skin is visible.
Mački razmaknite dlako na zatilju, da bo vidna koža.
Part the fur on the cat’s neck at the base of the skull until the skin is visible.
Razprite dlako na vratu zatilja glave, dokler ni vidna koža.
Part the hair and apply the contents of the pipette to a single spot on the skin of the dog at the base of the skull.
Razprite dlako in nanesite vsebino pipete na eno mesto kože vratu na zatilju glave psa.
Part the hair at the base of your animal’s neck in front of the shoulder blades to expose a small area of skin
Nanesite na kožo na predel zatilja, pred lopatici.
Part the hair at the base of your animal’s neck in front of the shoulder blades to expose a small area of skin.
Razmaknemo dlako v predelu zatilja (pred lopaticami), da se pokaže nekoliko kože.
Part the hair on the midline of the neck, between the base of the skull and the shoulder blades until the skin is visible.
Na sredini vratu med bazo lobanje in lopaticami, razmaknite dlako da postane koža vidna.
Part the hair until the skin is visible and place pipette tip against the skin between the shoulder blades.
Razmaknite dlako, da se vidi koža in nastavite merilno kapalko na kožo med lopaticama.
Part the hair until the skin is visible and place pipette tip against the skin between the shoulder blades.
Razmaknite dlako, da se vidi koža in nastavite vrh merilne kapalke na kožo med lopatice.
Partial
interval zaupanja]
Partial clearance ( ≥ 75%)
Delna ozdravitev (≥ 75 %)
Partial Clearance Rateb (≥ 75%)
Stopnja delne ozdravitveb (≥ 75 %)
partial loss of movement
delna izguba gibanja
partial loss of vision
delna izguba vida,
partial loss of vision, dry or painful eyes
delna izguba vida, suhe ali boleče oči
Partial Onset Seizures
Napadi parcialnega izvora
Partial Onset Seizures
Napadi s parcialnim izvorom
partial onset seizures with or without generalisation in adults, adolescents and children from 4 years of age
parcialnih napadov z generalizacijo ali brez nje odraslih, mladostnikih in otrocih od 4. leta starosti
partial onset seizures with or without generalisation in adults, adolescents and children from 4 years of age
parcialnih napadov z generalizacijo ali brez nje pri odraslih, mladostnikih in otrocih od 4. leta starosti
partial onset seizures with or without generalisation in adults, adolescents and children from 4 years of age
parcialnih napadov z generalizacijo ali brez nje pri odraslih, mladostnikih, otrocih in dojenčkih od 1 meseca starosti,
partial onset seizures with or without generalisation in adults, adolescents, children and infants from one month of age
parcialnih napadov z ali brez generalizacije pri odraslih, mladostnikih, otrocih in dojenčkih od 1 meseca dalje
partial onset seizures with or without generalisation in adults, adolescents, children and infants from one month of age
parcialnih napadov z generalizacijo ali brez nje pri odraslih, mladostnikih, otrocih in dojenčkih od 1 meseca dalje
partial onset seizures with or without generalisation in adults, adolescents, children and infants from one month of age
parcialnih napadov z generalizacijo ali brez nje pri odraslih, mladostnikih, otrocih in dojenčkih od 1 meseca starosti
partial onset seizures with or without generalisation in adults, adolescents, children and infants from one month of age
parcialnih napadov z generalizacijo ali brez nje pri odraslih, mladostnikih, otrocih in dojenčkih od 1 meseca starosti,
partial onset seizures with or without generalisation in adults, adolescents, children and infants from one month of age;
parcialnih napadov z ali brez generalizacije pri odraslih, mladostnikih, otrocih in dojenčkih od 1. meseca starosti;
partial onset seizures with or without generalisation in adults, adolescents, children and infants from one month of age;
parcialnih napadov z generalizacijo ali brez nje pri odraslih, mladostnikih, otrocih in dojenčkih od 1 meseca starosti
Partial or complete loss of vision in one or both eyes
Delna ali popolna izguba vida na enem ali obeh očesih
partial or total loss of vision
delna ali popolna izguba vida
Partial paralysis
Delna paraliza
partial paralysis
delna paraliza,
Partial remission(c,d)
Delno izboljšanje(c,d)
Partial remission4
Delna remisija4
Partial Responders (%)
Bolniki z delnim odzivom (%)
Partial responders**** in parent study (85)
Delno odzivni bolniki**** v predhodni študiji (85)
Partial response
Delni odgovor
Partial Response
Popoln odziv Delen odziv
Partial response %
Delni odgovor
Partial response (PR)
Delni odziv (PR)
Partial Response (PR) %
Delni odziv (PR)
Partial response (PR) [n (%)]
delni odziv (PR) [n (%)]
Partial responses
delni odzivi
Partial seizures are fits that start by only affecting one side of the brain.
Parcialni napadi so krči, ki na začetku prizadanejo samo eno stran možganov.
partial-onset seizures with or without generalisation in patients from 1 month of age; myoclonic seizures (short, shock-like jerks of a muscle or group of muscles) in patients from 12 years of age with juvenile myoclonic epilepsy;
napadov parcialnega izvora z generalizacijo ali brez nje pri bolnikih, starejših od enega meseca; miokloničnih napadov (kratkih, krču podobnih sunkovitih gibov mišice ali skupine mišic) pri bolnikih z juvenilno mioklonično epilepsijo od 12. leta starosti dalje;
partial-onset seizures with or without generalisation in patients from four years of age;
napadov parcialnega izvora z generalizacijo ali brez nje pri bolnikih od četrtega leta starosti dalje;
partial-onset seizures with or without generalisation in patients from four years of age;
napadov parcialnega izvora z generalizacijo ali brez nje pri bolnikih, starejših od štirih let;
partial-onset seizures with or without generalisation in patients from one month of age;
napadov parcialnega izvora z generalizacijo ali brez nje pri bolnikih, starejših od enega meseca;
Partially reversible dental caries were observed in mice treated for more than 1 month at exposure levels similar to the expected human exposure.
Pri miših, ki so aksitinib prejemale več kot 1 mesec pri stopnjah izpostavljenosti, ki so bile podobne pričakovani izpostavljenosti pri ljudeh, so opažali delno reverzibilno zobno gnilobo.
Partially used tablets to be used within 7 days.
Rok uporabnosti delno uporabljenih tablet je 7 dni.
Partially used vials must be discarded.
Delno porabljene viale je treba zavreči.
PARTIC ULARS TO APPEAR O N THE O UTER PACKAGING
PODATKI NA ZUNANJI OVOJNINI
Participants were randomised (1:1) to receive insulin glargine (n=6264), titrated to reach FPG ≤95 mg/dl (5.3 mM), or standard care (n=6273).
≤ 95 mg/dL (5,3 mM), ali na standardno oskrbo (n = 6273).
Participants were randomized (1:1) to receive insulin glargine (n=6264), titrated to reach FPG ≤95 mg/dL (5.3 mM), or standard care (n=6273).
Preiskovanci so po randomizaciji (1:1) prejemali insulin glargin (n=6264), titriran tako, da so dosegli FPG ≤95 mg/dl (5,3 mM), ali standardno zdravljenje.
Particular attention regarding the risk for infection should be paid when treating the elderly (see section 4.8).
Pri zdravljenju starostnikov je torej treba posvetiti posebno pozornost tveganju za nastanek okužbe (glejte poglavje 4.8).
Particular attention should be given to subjects suffering from epilepsy and the physician should inform the subjects (or parents) about the possibility to experience convulsion. (See section 4.8).
Posebno pozornost je treba posvetiti osebam, ki imajo epilepsijo, zdravnik pa mora osebe (ali starše) obvestiti o možnosti nastanka konvulzij (glejte poglavje 4.8).
Particular care should be exercised during individual dose titration.
Pri teh bolnikih je pri titriranju odmerka potrebna posebna previdnost.
Particular care should be taken when administering radioactive medicinal products to children and adolescents (from 2 to 16 years old).
Posebna previdnost je potrebna pri dajanju radiofarmakov otrokom in mladostnikom (starim od 2 do 16 let).
Particular care should be taken when administering radioactive medicinal products to children and adolescents.
Uporaba radioaktivnih zdravil pri otrocih in mladoletnikih zahteva posebno previdnost.
Particular care should be taken with regard to the accuracy of dosing including the use of an appropriate dosing device and careful estimation of body weight.
Bodite posebej pozorni na natančno odmerjanje, vključno z uporabo primerne priprave za odmerjanje, in na skrbno oceno telesne teže.
Particular care should be taken with regard to the accuracy of dosing including the use of an appropriate dosing device and careful estimation of bodyweight.
Bodite posebej pozorni na natančno odmerjanje, vključno z uporabo primerne priprave za odmerjanje, in na skrbno oceno telesne mase.
Particular care should be taken with regard to the accuracy of dosing including the use of an appropriate dosing device and careful estimation of bodyweight.
Bodite posebej pozorni na natančno odmerjanje, vključno z uporabo primerne priprave za odmerjanje, in na skrbno oceno telesne teže.
Particular care should be taken with regard to the accuracy of dosing.
Bodite zelo pozorni na uporabo pravilnega odmerka.
Particular care should be taken with regard to the accuracy of dosing.
Potrebna je zelo natančno doziranje.
Particular care should be taken with regard to the accuracy of dosing.
Potrebna je zelo natančno odmerjanje.
Particular caution is recommended in unstable asthma with variable use of rescue bronchodilators, in acute severe asthma as the associated risk may be augmented by hypoxia and in other conditions when the likelihood for hypokalaemia is increased.
Posebno previdnost priporočamo pri nestabilni astmi, kjer se uporabljajo različni bronhodilatatorji za nujne primere, pri hudi akutni astmi, saj lahko hipoksija dodatno poveča ogroženost bolnika, ter v drugih stanjih, kjer je verjetnost za pojav hipokaliemije kot neželenega učinka povečana.
Particular caution is recommended when nateglinide is co-administered with other more potent inhibitors of CYP2C9 (e.g. fluconazole, gemfibrozil or sulfinpyrazone), or in patients known to be poor metabolisers for CYP2C9.
Posebna previdnost je potrebna pri sočasni uporabi nateglinida z drugimi močnejšimi inhibitorji CYP2C9 (na primer s flukonazolom, z gemfibrozilom ali s sulfinpirazonom) ali pri bolnikih, za katere je znano, da imajo počasno presnovo, ki jo posreduje CYP2C9.
Particular caution is recommended when nateglinide is co-administered with other more potent inhibitors of CYP2C9, e.g. fluconazole or gemfibrozil, or in patients known to be poor metabolisers for CYP2C9.
Posebna previdnost je potrebna pri sočasni uporabi nateglinida z drugimi močnejšimi inhibitorji CYP2C9, na primer s flukonazolom ali gemfibrozilom, ali pri bolnikih, za katere je znano, da imajo počasno presnovo, ki jo posreduje CYP2C9.
Particular caution must be used when
midazolama pa je potrebna previdnost.
Particular caution should be exercised when administering amlodipine/valsartan to patients with mild to moderate hepatic impairment or biliary obstructive disorders.
Posebna previdnost je potrebna v primeru uporabe amlodipina/vlasartana pri bolnikih z blago do zmerno okvaro jeter ali z obstruktivnimi biliarnimi boleznimi.
Particular caution should be exercised when treating patients with previous abdominal surgery.
Posebno pozornost je treba nameniti zdravljenju bolnikov s predhodno abdominalno operacijo.
Particular caution should be used when prescribing EVOTAZ in association with medicinal products which have the potential to increase the QT interval and/or in patients with pre-existing risk factors (bradycardia, long congenital QT, electrolyte imbalances (see sections 4.8 and 5.3)).
Posebna previdnost je potrebna pri predpisovanju zdravila EVOTAZ skupaj z zdravili, ki lahko podaljšajo interval QT, in/ali bolnikih z že obstoječimi dejavniki tveganja (bradikardija, prirojeno podaljšanje intervala QT, neravnovesje elektrolitov (glejte poglavji 4.8 in 5.3)).
Particular caution should be used when prescribing Kaletra in patients taking digoxin as the acute inhibitory effect of ritonavir on Pgp is expected to significantly increase digoxin levels.
Posebna previdnost je potrebna pri predpisovanju zdravila Kaletra bolnikom, ki jemljejo digoksin, kajti pričakovati je treba, da akutno zavrtje Pgp z ritonavirjem bistveno zviša koncentracijo digoksina.
Particular caution should be used when prescribing REYATAZ in association with medicinal products which have the potential to increase the QT interval and/or in patients with pre- existing risk factors (bradycardia, long congenital QT, electrolyte imbalances (see sections 4.8 and 5.3).
Posebna previdnost je potrebna pri predpisovanju zdravila REYATAZ skupaj z zdravili, ki lahko podaljšajo interval QT, in/ali pri bolnikih z že obstoječimi dejavniki tveganja (bradikardija, prirojeno podaljšanje intervala QT, neravnovesje elektrolitov) (glejte poglavji 4.8 in 5.3).
Particular caution should be used when prescribing REYATAZ in association with medicinal products which have the potential to increase the QT interval and/or in patients with pre-existing risk factors (bradycardia, long congenital QT, electrolyte imbalances (see sections 4.8 and 5.3).
Posebna previdnost je potrebna pri predpisovanju zdravila REYATAZ skupaj z zdravili, ki lahko podaljšajo interval QT, in/ali pri bolnikih z že obstoječimi dejavniki tveganja (bradikardija, prirojeno podaljšanje intervala QT, neravnovesje elektrolitov) (glejte poglavji 4.8 in 5.3).
Particular caution should be used when titrating Effentora in patients with non-severe chronic obstructive pulmonary disease or other medical conditions predisposing them to respiratory depression, as even normally therapeutic doses of Effentora may further decrease respiratory drive to the point of respiratory failure.
Pri titriranju zdravila Effentora pri bolnikih z manj hudo obstruktivno pljučno boleznijo ali drugimi zdravstvenimi tegobami, zaradi katerih so nagnjenih k respiratorni depresiji, je potrebna posebna previdnost, saj lahko celo običajni terapevtski odmerki zdravila Effentora dodatno znižajo dihalno kapaciteto do take mere, da pride do dihalne odpovedi.
Particular diligence should be applied in initiating or maintaining effective hepatitis B therapy (referring to treatment guidelines) when starting dolutegravir-based therapy in hepatitis B co-infected patients (see section 4.8).
Posebna skrb je potrebna pri uvajanju ali vzdrževanju učinkovitega zdravljenja hepatitisa B (glede na smernice zdravljenja), kadar se začenja s terapijo na osnovi dolutegravirja pri bolnikih, ki so obenem okuženi tudi s hepatitisom B (glejte poglavje 4.8).
Particular risk of toxicity in relation to the amount of alcohol and propylene glycol contained in the oral solution of Norvir.
Posebno tveganje za toksične učinke glede na količino alkohola in propilenglikola v zdravilu Norvir peroralna raztopina.
particular when ribavirin is
če je ribavirin del
Particularly careful control of your diabetes, and prevention of hypoglycaemia, is important for the health of your baby.
Posebej skrben nadzor nad vašo sladkorno boleznijo in preprečevanje hipoglikemij sta pomembna za zdravje vašega otroka
Particularly careful control of your diabetes, and prevention of hypoglycaemia, is important for the health of your baby..
Posebej skrben nadzor nad vašo sladkorno boleznijo in preprečevanje hipoglikemij sta pomembna za zdravje vašega otroka.